Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis

Progress in Experimental Tumor Research

Volumn 37, Issue , 2003, Pages 179-192

  Gately, Stephen ^a   Kerbel, Robert ^b  

^a NeoPharm Inc   (United States)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIAL CELL GROWTH FACTOR; ISOENZYME; LYMPHOKINE; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; SIGNAL PEPTIDE; THROMBOXANE A2; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL; APOPTOSIS; DRUG ANTAGONISM; HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; REVIEW; VASCULARIZATION;

ANIMALS; APOPTOSIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENDOTHELIAL GROWTH FACTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; LYMPHOKINES; MEMBRANE PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THROMBOXANE A2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0042131613     PISSN: 00796263     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000071373     Document Type: Article

References (131)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
2. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-1201.
3. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, Bader BL, Hynes RO, Zhuang Y, Manova K, Benezra R: Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999;401:670-677.
4. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
5. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991;66:1095-1104.
6. Reinmuth N, Stoeltzing O, Liu W, Ahmad SA, Jung YD, Fan F, Parikh A, Ellis LM: Endothelial survival factors as targets for antineoplastic therapy. Cancer J 2001;7(suppl 3):109-119.
7. Ellis LM, Liu W, Ahmad SA, Fan F, Jung YD, Shaheen RM, Reinmuth N: Overview of angiogenesis: Biologic implications for antiangiogenic therapy. Semin Oncol 2001;28:94-104.
8. Pepper MS, Montesano R: Proteolytic balance and capillary morphogenesis. Cell Differ Dev 1990;32:319-327.
9. Subbaramaiah K, Telang N, Bansal MB, Weksler BB, Dannenberg AJ: Cyclooxygenase-2 gene expression is upregulated in transformed mammary epithelial cells. Ann NY Acad Sci 1997;833: 179-185.
10. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Dannenberg AJ: Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 1997;57:2890-2895.
11. Paku S, Paweletz N: First steps of tumor-related angiogenesis. Lab Invest 1991;65:334-346.
12. Paku S: Current concepts of tumor-induced angiogenesis. Pathol Oncol Res 1998;4:62-75.
13. Risau W, Flamme I: Vasculogenesis. Annu Rev Cell Dev Biol 1995;11:73-91.
14. Rafii S, Meeus S, Dias S, Hattori K, Heissig B, Shmelkov S, Rafii D, Lyden D: Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol 2002; 13:61-67.
15. Benezra R, Rafii S, Lyden D: The Id proteins and angiogenesis. Oncogene 2001;20:8334-8341.
16. Rafii S: Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest 2000;105:17-19.
17. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR, Moore MA, Storb RF, Hammond WP: Evidence for circulating bone marrow-derived endothelial cells. Blood 1998;92:362-367.
18. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S: Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-958.
19. Folkman J: Looking for a good endothelial address. Cancer Cell 2002;1:113-115.
20. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
21. Lannutti BJ, Gately ST, Quevedo ME, Soff GA, Paller AS: Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 1997;57:5277-5280.
22. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
23. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA: The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997; 94:10868-10872.
24. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998;394:287-291.
25. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-407.
26. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62:625-631.
27. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
28. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
29. DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, van de Putte LB, Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
30. Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hla T: Induction of cyclooxygenase-2 by interleukin-1α. Evidence for post-transcriptional regulation. J Biol Chem 1994;269:11769-11775.
31. Yan X, Wu XC, Sun M, Tsang BK, Gibb W: Nuclear factor κB activation and regulation of cyclooxygenase type-2 expression in human amnion mesenchymal cells by interleukin-1β. Biol Reprod 2002;66:1667-1671.
32. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ: Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001;7:429-434.
33. 1 and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasia 1999;1:508-517.
34. 1 in immortalized mouse colonocytes expressing oncogenic Ras. J Gastrointest Surg 2002;6:304-309.
35. 2 release in human airway smooth muscle cells. Am J Physiol 2000;279:L201-L207.
36. Mark KS, Trickler WJ, Miller DW: Tumor necrosis factor-α induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells. J Pharmacol Exp Ther 2001;297:1051-1058.
37. Fosslien E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000;30:3-21.
38. Δ716 knockout mice by inhibition of cyclooxygenase 2. Cell 1996;87:803-809.
39. Δ716 mouse intestinal polyps. Cancer Res 2002;62:506-511.
40. Dannenberg AJ, Altorki NK, Boyle JO, Lin DT, Subbaramaiah K: Inhibition of cyclooxygenase-2: An approach to preventing cancer of the upper aerodigestive tract. Ann NY Acad Sci 2001;952:109-115.
41. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
42. Kirschenbaum A, Liu X, Yao S, Levine AC: The role of cyclooxygenase-2 in prostate cancer. Urology 2001;58:127-131.
43. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-1594.
44. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori M: Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999;79:1469-1477.
45. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ: Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999;274:10911-10915.
46. Galy B, Creancier L, Prado-Lourenco L, Prats AC, Prats H: p53 directs conformational change and translation initiation blockade of human fibroblast growth factor 2 mRNA. Oncogene 2001;20:4613-4620.
47. Ueba T, Nosaka T, Takahashi JA, Shibata F, Florkiewicz RZ, Vogelstein B, Oda Y, Kikuchi H, Hatanaka M: Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci USA 1994;91:9009-9013.
48. Yuan A, Yu CJ, Luh KT, Kuo SH, Lee YC, Yang PC: Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol 2002;20:900-910.
49. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-1584.
50. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-1423.
51. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999;59:4574-4577.
52. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70.
53. Cordon-Cardo C, Prives C: At the crossroads of inflammation and tumorigenesis. J Exp Med 1999;190:1367-1370.
54. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D: Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999;13:1382-1397.
55. Michalowski J: COX-2 inhibitors: Cancer trials test new uses for pain drug. J Natl Cancer Inst 2002;94:248-249.
56. Jones MK, Szabo IL, Kawanaka H, Husain SS, Tarnawski AS: Von Hippel-Lindau tumor suppressor and HIF-1α: New targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB J 2002;16:264-266.
57. Chiarugi V, Magnelli L, Gallo O: Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review). Int J Mol Med 1998;2:715-719.
58. Ji YS, Xu Q, Schmedtje JF Jr: Hypoxia induces high-mobility-group protein I(Y) and transcription of the cyclooxygenase-2 gene in human vascular endothelium. Circ Res 1998;83:295-304.
59. Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN, Runge MS: Hypoxia induces cyclooxygenase-2 via the NF-κB p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997;272:601-608.
60. Maxwell PH, Ratcliffe PJ: Oxygen sensors and angiogenesis. Semin Cell Dev Biol 2002;13:29-37.
61. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
62. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L: A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995;182:1683-1693.
63. Yan SF, Tritto I, Pinsky D, Liao H, Huang J, Fuller G, Brett J, May L, Stern D: Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J Biol Chem 1995;270:11463-11471.
64. Hirani N, Antonicelli F, Strieter RM, Wiesener MS, Ratcliffe PJ, Haslett C, Donnelly SC: The regulation of interleukin-8 by hypoxia in human macrophages - A potential role in the pathogenesis of the acute respiratory distress syndrome. Mol Med 2001;7:685-697.
65. Willam C, Koehne P, Jurgensen JS, Grafe M, Wagner KD, Bachmann S, Frei U, Eckardt KU: TIE-2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. Circ Res 2000;87:370-377.
66. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B: Tumor induction of VEGF promoter activity in stromal cells. Cell 1998;94:715-725.
67. Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M: Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000;130:641-649.
68. 2 modulation of vascular endothelial growth factor production in murine macrophages. Prostaglandins Leukot Essent Fatty Acids 2001;65:123-131.
69. 2/JNK1 signaling pathways. Biochem Biophys Res Commun 2001;286:923-928.
70. 1-induced vascular endothelial growth factor synthesis in osteoblasts. J Endocrinol 2001;170:629-638.
71. 2 of the production of interleukin-6, macrophage colony-stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol 2002;136:287-295.
72. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R, Masini E: Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001;121:1339-1347.
73. Δ716 knockout mice. Nat Med 2001;7:1048-1051.
74. Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M, Pagano JS: Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001;98:6905-6910.
75. Rak J, Filmus J, Kerbel RS: Reciprocal paracrine interactions between tumour cells and endothelial cells: The 'angiogenesis progression' hypothesis. Eur J Cancer 1996;32A:2438-2450.
76. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
77. 2 regulation of endothelial cell migration, angiogenesis and tumor metastasis. Biochem Biophys Res Commun 2000;267:245-251.
78. Herschman HR, Xie W, Reddy S: Inflammation, reproduction, cancer and all that.... The regulation and role of the inducible prostaglandin synthase. Bioessays 1995;17:1031-1037.
79. Zachary I: Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001;280:C1375-C1386.
80. Krishnamurthy P, Bird IM, Sheppard C, Magness RR: Effects of angiogenic growth factors on endothelium-derived prostacyclin production by ovine uterine and placental arteries. Prostaglandins Other Lipid Mediat 1999;57:1-12.
81. 2. Proc Natl Acad Sci USA 1989;86:1573-1577.
82. Gurubhagavatula I, Amrani Y, Pratico D, Ruberg FL, Albelda SM, Panettieri RA Jr: Engagement of human PECAM-1 (CD31) on human endothelial cells increases intracellular calcium ion concentration and stimulates prostacyclin release. J Clin Invest 1998;101:212-222.
83. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM: Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998;97:99-107.
84. 1 and copper in angiogenesis. J Natl Cancer Inst 1982;69:475-482.
85. Gullino PM, Ziche M, Alessandri G: Gangliosides, copper ions and angiogenic capacity of adult tissues. Cancer Metastasis Rev 1990;9:239-251.
86. Ziche M, Alessandri G, Gullino PM: Gangliosides promote the angiogenic response. Lab Invest 1989;61:629-634.
87. Ziche M, Morbidelli L, Alessandri G, Gullino PM: Angiogenesis can be stimulated or repressed in vivo by a change in GM3:GD3 ganglioside ratio. Lab Invest 1992;67:711-715.
88. 1 in rabbit cornea. Adv Prostaglandin Thromboxane Leukot Res 1995;23:495-497.
89. 2 and angiogenesis. Proc Soc Exp Biol Med 1983;172:214-218.
90. Ben-Av P, Crofford LJ, Wilder RL, Hla T: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis. FEBS Lett 1995;372:83-87.
91. Harada S, Rodan SB, Rodan GA: Expression and regulation of vascular endothelial growth factor in osteoblasts. Clin Orthop 1995;76-80.
92. 1 in osteoblasts. J Clin Invest 1994;93:2490-2496.
93. 2. Anat Rec 1994;238:68-76.
94. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer cell line HT-29. J Biol Chem 2002;277:27613-27621.
95. Elder DJ, Halton DE, Playle LC, Paraskeva C: The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer 2002;99:323-327.
96. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-18569.
97. 2 in human colon cancer cells. Cancer Res 1998;58:362-366.
98. Parfenova H, Parfenov VN, Shlopov BV, Levine V, Falkos S, Pourcyrous M, Leffler CW: Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells. Am J Physiol 2001;281:C166-C178.
99. Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM, Polverini PJ: Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001;61:2183-2188.
100. Nor JE, Christensen J, Mooney DJ, Polverini PJ: Vascular endothelial growth factor-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999;154:375-384.
101. Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML: Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2001;276:48997-49002.
102. Sheng H, Shao J, DuBois RN: K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res 2001;61:2670-2675.
103. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS: A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002;99:4349-4354.
104. Dimmeler S, Zeiher AM: Akt takes center stage in angiogenesis signaling. Circ Res 2000;86:4-5.
105. Patti R, Gumired K, Reddanna P, Sutton LN, Phillips PC, Reddy CD: Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: Effect of celecoxib and rofecoxib. Cancer Lett 2002;180:13-21.
106. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-11403.
107. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS: Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol 2000;40:124-132.
108. Clemett D, Goa KL: Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000;59:957-980.
109. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
110. Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, Bolognese J, Seidenberg B, Ehrich EW: The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 1999; 21:1688-1702.
111. Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992;52:6702-6704.
112. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP, Soff GA, Kufe DW, Weichselbaum RR: Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998;58:5686-5689.
113. Milas L: Cyclooxygenase-2 enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 2001;11:290-299.
114. Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ: Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000;6:2513-2520.
115. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, Tofilon PJ, Milas L: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000;60:1326-1331.
116. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous lowdose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-R24.
117. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer. Cancer Res 2000;60:1878-1886.
118. Gately S, Kerbel R: Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001;7:427-436.
119. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS: Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-2735.
120. Garber K: Could less be more? Low-dose chemotherapy goes on trial. J Natl Cancer Inst 2002;94:82-84.
121. Gasparini G: Metronomic scheduling: The future of chemotherapy? Lancet Oncol 2001;2:733-740.
122. Kerbel RS, Klement G, Pritchard KI, Kamen B: Continuous low-dose anti-angiogenic/ metronomic chemotherapy: From the research laboratory into the oncology clinic. Ann Oncol 2002;13:12-15.
123. Marx J: Cancer research. Anti-inflammatories inhibit cancer growth - but how? Science 2001;291:581-582.
124. Hwang DH, Fung V, Dannenberg AJ: National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia 2002;4:91-97.
125. Hawk ET, Viner JL, Dannenberg A, DuBois RN: COX-2 in cancer - a player that's defining the rules. J Natl Cancer Inst 2002;94:545-546.
126. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN: Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000;60:6045-6051.
127. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS: Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;94:585-591.
128. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
129. Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
130. Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, Hanahan D: Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996;93:2002-2007.
131. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-812.